// App-Quantinova.ai

[FRI0482] : SAFETY AND TOLERABILITY OF MEDI-551 IN SUBJECTS WITH SYSTEMIC SCLEROSIS (SSC): RESULTS FROM A PHASE 1 RANDOMIZED, PLACEBO-CONTROLLED ESCALATING SINGLE-DOSE STUDY

Researchers

Presenter

  • E. Schiopu

Principal Investigators

  • S. CHATTERJEE

  • V. Hsu

  • A. Flor

  • D. Pavlovic

  • K. Patra

  • J. Li

  • K. McKeever

  • R. Herbst

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Arrhythmia

  • Cardiorenal syndrome

  • Scleroderma

  • Renal disease

  • Venous thrombosis

  • Myositis

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • Cluster of Differentiation 19

Drug/Treatment

  • MEDI 551

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved